Antibody-Drug Conjugate Manufacturing Systems

Integrated manufacturing solutions supporting the safe production of high-potency antibody-drug conjugates.

Antibody-drug conjugates combine the targeting capability of monoclonal antibodies with highly potent cytotoxic payloads used in oncology therapies. These complex biologics require specialized manufacturing environments capable of safely handling high-potency compounds while maintaining strict control over product quality.

ZETA supports ADC manufacturing with integrated process systems designed for conjugation reactions, purification, formulation, and high-containment handling. Our engineering expertise enables manufacturers to establish GMP-compliant production environments that support both clinical and commercial ADC manufacturing.

ADC production requires high‑containment environments to safely manage potent cytotoxic compounds. Closed processing, contained powder handling, efficient filtration, and pressure‑controlled cleanrooms (OEB5/OEB6) ensure operator protection and GMP compliance.

ZETA integrates antibody production, conjugation, filtration, and buffer/media preparation into a seamless, controlled workflow for safe and consistent ADC manufacturing.

Automated CIP and contained waste‑handling systems complete the containment strategy, ensuring safe residue removal and full regulatory compliance.

ADC manufacturing facilities require careful planning to integrate containment, process systems, and automation within a compliant production environment.

ZETA works with pharmaceutical manufacturers to design and implement modular process systems that support safe and reliable ADC production. Our engineering expertise enables manufacturers to develop facilities capable of producing both clinical-stage and commercial ADC products while maintaining strict regulatory compliance.